RxDoctor Payments Data

Carl Shealy, MD

Nephrology · Columbia, SCNPI 1861467235

Payments from drug & device makers

$3,797in general payments, 2019–2025

Across 153 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$588
  • Nxstage Medical, Inc.$497
  • Calliditas Therapeutics US Inc.$295
  • Travere Therapeutics, Inc.$270
  • Mallinckrodt Hospital Products Inc.$269
  • Otsuka America Pharmaceutical, Inc.$261
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,74399%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,797 in reported general payments places this provider in the 60th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$208,875
Medicare patients
522
Services billed
3,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide43$119,433
AuryxiaFerric Citrate15$44,031
ProcritEpoetin Alfa39$37,319
FarxigaDapagliflozin Propanediol42$35,365
Sevelamer Carbonate13$4,285
RetacritEpoetin Alfa-Epbx15$3,350
Valsartan81$1,493
Torsemide21$1,244
Calcitriol54$893
Irbesartan11$596
Furosemide80$465
Spironolactone29$360
Lisinopril26$342
Potassium Chloride29$319
Losartan Potassium21$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$93$119,43343 claims
Akebia Therapeutics IncAuryxia$80$44,03115 claims
AstraZenecaFarxiga$251$35,36542 claims
ANI Pharmaceuticals, Inc.Valsartan$47$1,49381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →